De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset

摘要: In contrast to levodopa (L-dopa), de novo administration of the D2-like receptor agonist bromocriptine patients with Parkinson's disease (PD) or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated subhuman primates is not associated onset significant dyskinesia. We now compare ability novel selective dopamine ropinirole that and L-dopa induce dyskinesia in MPTP-treated common marmosets. marmosets were treated placebo, plus carbidopa, ropinirole, daily for 30 days (n = 4 per group) doses titrated similarly increase locomotion improve motor disability. rapidly induced moderate severe intensity, whereas produced mild over course study was significantly less than L-dopa-treated group (p < 0.05). However, a separate previously primed exhibit dyskinesia, elicited dyskinesias comparable dose-dependent fashion. Ropinirole, bromocriptine, has lesser tendency produce while improving performance drug-naive other agonists, will elicit once priming occurred. These results predict similar response long-acting agonists L-dopa-naive PD emphasize importance avoiding initial induction through early use drugs.